Cohort profile : a nationwide population-based retrospective assessment of oesophageal cancer in the Finnish National Esophago-Gastric Cancer Cohort (FINEGO)

Purpose The Finnish National Esophago-Gastric Cancer Cohort (FINEGO) was established to combine the available registry data with detailed patient information to form a comprehensive, retrospective, population-based research platform of surgically treated oesophageal and gastric cancer in Finland. This cohort profile describes the 2045 surgically treated patients with oesophageal cancer included in the FINEGO cohort. Participants Registry data were collected from the National Cancer, Patient, Education and Death Registries from 1 January 1987 to 31 December 2016. All patients over 18 years of age, who had either curative surgery, palliative surgery or salvage surgery for primary cancer in the oesophagus are included in this study. Findings to date 2045 patients had surgery for oesophageal cancer in the selected time period. 67.2% were man, and the majority had only minor comorbidities. The proportions of adenocarcinomas and squamous cell carcinomas were 43.1% and 44.4%, respectively, and 12.5% had other or missing histology. Only about 23% of patients received neoadjuvant therapy. Oesophagectomy was the treatment of choice and most patients were treated at low-volume centres, but median annual hospital volume increased over time. Median overall survival was 23 months, 5-year survival for all patients in the cohort was 32.9% and cancer-specific survival was 36.5%. Future plans Even though Finland only has a population of 5.5 million, surgery for oesophageal carcinoma has not been centralised and therefore previously reported results have mostly been small, single-centre cohorts. Because of FINEGO, we now have a population-based, unselected cohort of surgically treated patients, enabling research on national trends over time regarding oesophageal cancer, including patient characteristics, tumour histology, stage and neoadjuvant treatment, surgical techniques, hospital volumes and patient mortality. Data collection is ongoing, and the cohort will be expanded to include more detailed data from patient records and national biobanks.Peer reviewe

Cohort profile: gastric cancer in the population-based, Finnish National Esophago-Gastric Cancer Cohort (FINEGO) Study

Purpose The Finnish National Esophago-Gastric Cancer Cohort (FINEGO) was established with the aim of identifying factors that could contribute to improved outcomes in oesophago-gastric cancer. The aim of this study is to describe the patients with gastric cancer included in FINEGO. Participants A total of 10 457 patients with gastric cancer or tumour diagnosis in the Finnish Cancer Registry or the Finnish Patient Registry during 1987-2016 were included in the cohort, with follow-up from Causes of Death Registry until 31 December 2016. All of the participants were at least 18 years of age, and had undergone either resectional or endoscopic mucosal surgery with curative or palliative intent. Findings to date Of the 10 457 patients, 90.1% were identified to have cancer in both cancer and patient registries. In all, the median age was 70 at the time of surgery, 54.5% of the patients were men and 64.4% had no comorbidities. Education data were available for 31.1% of the patients, of whom the majority had had Future plans The data in FINEGO can be currently used for registry-based research but is being expanded by data extraction from patient records and scanning of histological samples from the Finnish biobanks. Initially, we are planning on studies on the national trends in treatment and mortality, and studies on the demographic factors and their influence on survival.</div

Cohort profile: a nationwide population-based retrospective assessment of oesophageal cancer in the Finnish National Esophago-Gastric Cancer Cohort (FINEGO)

Purpose The Finnish National Esophago-Gastric Cancer Cohort (FINEGO) was established to combine the available registry data with detailed patient information to form a comprehensive, retrospective, population-based research platform of surgically treated oesophageal and gastric cancer in Finland. This cohort profile describes the 2045 surgically treated patients with oesophageal cancer included in the FINEGO cohort. Participants Registry data were collected from the National Cancer, Patient, Education and Death Registries from 1 January 1987 to 31 December 2016. All patients over 18 years of age, who had either curative surgery, palliative surgery or salvage surgery for primary cancer in the oesophagus are included in this study. Findings to date 2045 patients had surgery for oesophageal cancer in the selected time period. 67.2% were man, and the majority had only minor comorbidities. The proportions of adenocarcinomas and squamous cell carcinomas were 43.1% and 44.4%, respectively, and 12.5% had other or missing histology. Only about 23% of patients received neoadjuvant therapy. Oesophagectomy was the treatment of choice and most patients were treated at low-volume centres, but median annual hospital volume increased over time. Median overall survival was 23 months, 5-year survival for all patients in the cohort was 32.9% and cancer-specific survival was 36.5%. Future plans Even though Finland only has a population of 5.5 million, surgery for oesophageal carcinoma has not been centralised and therefore previously reported results have mostly been small, single-centre cohorts. Because of FINEGO, we now have a population-based, unselected cohort of surgically treated patients, enabling research on national trends over time regarding oesophageal cancer, including patient characteristics, tumour histology, stage and neoadjuvant treatment, surgical techniques, hospital volumes and patient mortality. Data collection is ongoing, and the cohort will be expanded to include more detailed data from patient records and national biobanks

Raskausdiabeetikoiden kokemuksia liikunta- ja ruokavalio-ohjauksesta

Vielä kaksikymmentä vuotta sitten raskausdiabetekseen sairastui vain noin 1 % raskaana olevista. Tämän jälkeen raskausdiabetes on maailmanlaajuisesti yleistynyt. Suomessa sairaanhoitopiiristä ja osittain diagnostisista kriteereistä riippuen jopa 25 % raskaana olevista sairastuu raskausdiabetekseen. Raskausdiabetes lisää terveydenhuollon kustannuksia altistamalla tyypin 2 diabetekselle sekä aiheuttamalla synnytyskomplikaatioita. Elintapojen muutoksen on todettu vaikuttavan positiivisesti raskausdiabeteksen taustalla olevaan sokeri-aineenvaihdunnan häiriöön. (THL 2011, hakupäivä 29.9.2013.) Tutkimuksemme tarkoituksena oli kuvailla raskausdiabeetikkojen kokemuksia saamastaan liikunta- ja ruokavalio-ohjauksesta raskausdiabeteksen hoitamiseksi. Tutkimuksen teoriaperustana käytettiin kirjallisuutta, aiheesta julkaistuja kotimaisia ja muutamia ulkomaisia tutkimuksia, tieteellisiä julkaisuja, sekä internetlähteitä. Tutkimus toteutettiin laadullisena tutkimuksena. Aineisto kerättiin avoimen kyselylomakkeen avulla. Palautettuja vastauksia saatiin yhteensä 11 kappaletta. Vastaukset analysoitiin sisällönanalyysi menetelmällä. Raskausdiabeetikot kokivat saaneensa yksilöllistä, toiminnan muutokseen johtavaa ohjausta. Ohjaustilanne koettiin positiivisena. Yksilöllisestä ohjauksesta huolimatta osa vastaajista koki henkilökohtaisen näkökulman puuttuneen ohjaustilanteesta. Vastaajat toivoivat lisää resursseja ohjaukseen. Tulosten avulla raskausdiabeteksen parissa työskentelevien on mahdollista kehittää raskausdiabeetikoiden ruokavalio- ja elintapaohjausta potilaslähtöisemmäksi. Ruokavalio-ohjauksen antaminen toteutui erityisen hyvin. Liikunnanohjauksen suhteen ohjausta tulee kehittää. Koska useilla vastaajista liikunnan lisääminen ei toteutunut liikunnanohjauksessa voi hyödyntää hyöty- ja arkiliikunnan käyttöönottoa. Yksilöllisyyden huomioiminen ohjauksessa herätti ristiriitaisia tunteita. Taustatietojen kartoittamisen jälkeen ohjauksen tarpeisiin tulee kiinnittää erityistä huomiota. Resurssien lisääminen on hankalaa, joten tehostettu tarpeiden määritys voi helpottaa ajankäyttöön liittyviä ongelmia. Tutkimusta voi jatkaa tutkimalla raskausdiabeetikkojen terveyskäyttäytymistä muutaman vuoden kuluttua; onko uudet elintavat omaksuttu koko perheen elintavoiksi, vieläkö niitä noudatetaan ja jatkuuko elintapaohjaus lapsen syntymän jälkeen.Gestational diabetes has increased globally over twenty years. In Finland even 25% of pregnant women are diagnosed in gestational diabetes. Gestational diabetes increases costs in healthcare by exposing women to the diabetes mellitus type 2 and causing complication in labour. Life style changes have shown positive changes in sugar metabolism, which is said to be a reason for the gestational diabetes. The aim of the thesis was to describe the experiences of exercise and diet counseling among the women who were diagnosed with gestational diabetes. The aim was also to get information on how to improve guidance. Our study was qualitative. The material was collected with questionnaires with open-ended questions. We got eleven questionnaires returned. We analyzed the answers using the content analysis methodology. Gestational diabetics described counseling to be individual, positive and also motivating to change the lifestyle. According to the informants resources must be increased to improve the guidance. With this study we can give more possibilities to the people who work with gestational diabetics to develop the guidance to be more patient-oriented. Further research could be targeted at gestational diabetics' change of lifestyle after a couple of years. The study could examine if the diabetics and their family had adopted a new lifestyle as to exercise and diet

Cohort profile : gastric cancer in the population-based, Finnish National Esophago-Gastric Cancer Cohort (FINEGO) Study

Purpose The Finnish National Esophago-Gastric Cancer Cohort (FINEGO) was established with the aim of identifying factors that could contribute to improved outcomes in oesophago-gastric cancer. The aim of this study is to describe the patients with gastric cancer included in FINEGO. Participants A total of 10 457 patients with gastric cancer or tumour diagnosis in the Finnish Cancer Registry or the Finnish Patient Registry during 1987-2016 were included in the cohort, with follow-up from Causes of Death Registry until 31 December 2016. All of the participants were at least 18 years of age, and had undergone either resectional or endoscopic mucosal surgery with curative or palliative intent. Findings to date Of the 10 457 patients, 90.1% were identified to have cancer in both cancer and patient registries. In all, the median age was 70 at the time of surgery, 54.5% of the patients were men and 64.4% had no comorbidities. Education data were available for 31.1% of the patients, of whom the majority had hadPeer reviewe

Cohort profile: gastric cancer in the population-based, Finnish National Esophago-Gastric Cancer Cohort (FINEGO) Study

Abstract Purpose: The Finnish National Esophago-Gastric Cancer Cohort (FINEGO) was established with the aim of identifying factors that could contribute to improved outcomes in oesophago-gastric cancer. The aim of this study is to describe the patients with gastric cancer included in FINEGO. Participants: A total of 10 457 patients with gastric cancer or tumour diagnosis in the Finnish Cancer Registry or the Finnish Patient Registry during 1987–2016 were included in the cohort, with follow-up from Causes of Death Registry until 31 December 2016. All of the participants were at least 18 years of age, and had undergone either resectional or endoscopic mucosal surgery with curative or palliative intent. Findings: to date Of the 10 457 patients, 90.1% were identified to have cancer in both cancer and patient registries. In all, the median age was 70 at the time of surgery, 54.5% of the patients were men and 64.4% had no comorbidities. Education data were available for 31.1% of the patients, of whom the majority had had &lt;12 years of formal education. Of the 7798 with cancer staging data available, 41.1% had a local cancer. Adenocarcinoma was the most common (94.2%) histological type. Almost all patients underwent open gastrectomy and 214% in hospitals with annual volume of more than 30 gastrectomies per year. A total of 8561 deaths occurred during the study period, of which 6474 were due to oesophago-gastric cancers. The 5-year survival was 34.6% and 5-year cancer-specific survival was 39.7%. Future plans: The data in FINEGO can be currently used for registry-based research but is being expanded by data extraction from patient records and scanning of histological samples from the Finnish biobanks. Initially, we are planning on studies on the national trends in treatment and mortality, and studies on the demographic factors and their influence on survival

Cohort profile:a nationwide population-based retrospective assessment of oesophageal cancer in the Finnish National Esophago-Gastric Cancer Cohort (FINEGO)

Abstract Purpose: The Finnish National Esophago-Gastric Cancer Cohort (FINEGO) was established to combine the available registry data with detailed patient information to form a comprehensive, retrospective, population-based research platform of surgically treated oesophageal and gastric cancer in Finland. This cohort profile describes the 2045 surgically treated patients with oesophageal cancer included in the FINEGO cohort. Participants: Registry data were collected from the National Cancer, Patient, Education and Death Registries from 1 January 1987 to 31 December 2016. All patients over 18 years of age, who had either curative surgery, palliative surgery or salvage surgery for primary cancer in the oesophagus are included in this study. Findings to date: 2045 patients had surgery for oesophageal cancer in the selected time period. 67.2% were man, and the majority had only minor comorbidities. The proportions of adenocarcinomas and squamous cell carcinomas were 43.1% and 44.4%, respectively, and 12.5% had other or missing histology. Only about 23% of patients received neoadjuvant therapy. Oesophagectomy was the treatment of choice and most patients were treated at low-volume centres, but median annual hospital volume increased over time. Median overall survival was 23 months, 5-year survival for all patients in the cohort was 32.9% and cancer-specific survival was 36.5%. Future plans: Even though Finland only has a population of 5.5 million, surgery for oesophageal carcinoma has not been centralised and therefore previously reported results have mostly been small, single-centre cohorts. Because of FINEGO, we now have a population-based, unselected cohort of surgically treated patients, enabling research on national trends over time regarding oesophageal cancer, including patient characteristics, tumour histology, stage and neoadjuvant treatment, surgical techniques, hospital volumes and patient mortality. Data collection is ongoing, and the cohort will be expanded to include more detailed data from patient records and national biobanks